What Happened?
The trial aimed to reduce proteinuria in IgA nephropathy patients but did not show a statistically significant improvement compared to a placebo. As a result, Omeros will not seek approval for narsoplimab in this indication and will discontinue the ARTEMIS-IGAN trial.
The company plans to redirect funds to other programs, including OMS906, and is focused on resubmitting its application for narsoplimab in another medical condition.
The company says the drug has demonstrated good safety in this study. Omeros will discuss these results in a conference call today.
See Also: Drug Retailer Rite Aid Grappling With Lawsuits Files For Bankruptcy
According to data from Benzinga Pro, OMER has a 52-week high of $7.80 and a 52-week low of $1.74.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
